Literature DB >> 15588753

Ketamine-induced changes in rat behaviour: a possible animal model of schizophrenia. Test of predictive validity.

Axel Becker1, Gisela Grecksch.   

Abstract

Previously, it was shown that subchronic application of the NMDA receptor antagonist ketamine (Ket) induces schizophrenia-related alterations, e.g. decreased non-aggressive behaviour in the social interaction test, which might be a useful animal model in the study of negative symptoms of this disease. In order to further evaluate the predictive validity of this model, the anxioloytic diazepam, the classic neuroleptic haloperidol and the atypical neuroleptics clozapine and risperidone were tested after acute and subchronic treatment. The experiments demonstrated that haloperidol did not normalise the behavioural effects of Ket. After acute administration, diazepam was ineffective in control animals but increased non-aggressive behaviour in Ket-treated animals. Similar effects were found in animals injected with either clozapine or risperidone. Twenty-four hours after discontinuation of subchronic treatment with both substances, there was an increase in the percentage of non-aggressive behaviour in the ketamine group and a decrease in the control animals. This decrease was explained in terms of withdrawal. Different effects in the control groups and the Ket groups were found when the test was performed 1 h after subchronic clozapine or risperidone treatment. The data suggest that atypical antipsychotic drugs (APD) effectively counteract Ket-induced alterations in social behaviour. Regarding false-positive effects by anxiolytic drugs without antipsychotic efficacy, this model may have some predictive validity for identifying anxiolytic effects of novel antipsychotic compounds.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15588753     DOI: 10.1016/j.pnpbp.2004.06.019

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  26 in total

1.  Probable mechanisms involved in the antipsychotic-like activity of methyl jasmonate in mice.

Authors:  Olajide S Annafi; Oritoke M Aluko; Anthony T Eduviere; Osarume Omorogbe; Solomon Umukoro
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2017-06-13       Impact factor: 3.000

2.  Comparative effects of sertraline, haloperidol or olanzapine treatments on ketamine-induced changes in mouse behaviours.

Authors:  O J Onaolapo; T B Paul; A Y Onaolapo
Journal:  Metab Brain Dis       Date:  2017-05-15       Impact factor: 3.584

3.  Pain sensitivity is altered in animals after subchronic ketamine treatment.

Authors:  Axel Becker; Gisela Grecksch; Helmut Schröder
Journal:  Psychopharmacology (Berl)       Date:  2006-10-03       Impact factor: 4.530

4.  The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia.

Authors:  Ayan Ghoshal; P Jeffrey Conn
Journal:  Future Neurol       Date:  2015

5.  Maternal deprivation disrupts mitochondrial energy homeostasis in the brain of rats subjected to ketamine-induced schizophrenia.

Authors:  Alexandra Ioppi Zugno; Felipe Damázio Pacheco; Josiane Budni; Mariana Bittencourt de Oliveira; Lara Canever; Alexandra Stephanie Heylmann; Patrícia Gomes Wessler; Flávia da Rosa Silveira; Gustavo Antunes Mastella; Cinara Ludwig Gonçalves; Karoline V Freitas; Adalberto Alves de Castro; Emilio L Streck; João Quevedo
Journal:  Metab Brain Dis       Date:  2015-04-30       Impact factor: 3.584

6.  Juvenile exposure to ketamine causes delayed emergence of EEG abnormalities during adulthood in mice.

Authors:  R E Featherstone; L R Nagy; C G Hahn; S J Siegel
Journal:  Drug Alcohol Depend       Date:  2013-09-27       Impact factor: 4.492

7.  Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia.

Authors:  Axel Becker; Gisela Grecksch; Gerald Zernig; Elisabeth Ladstaetter; Christoph Hiemke; Ulrich Schmitt
Journal:  Psychopharmacology (Berl)       Date:  2008-09-23       Impact factor: 4.530

8.  Risperidone and haloperidol promote survival of stem cells in the rat hippocampus.

Authors:  Gerburg Keilhoff; Gisela Grecksch; Hans-Gert Bernstein; Thomas Roskoden; Axel Becker
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-05       Impact factor: 5.270

9.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

Review 10.  From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and long-term adverse consequences of drug use?

Authors:  I S McGregor; P D Callaghan; G E Hunt
Journal:  Br J Pharmacol       Date:  2008-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.